By Rebecca Ann Hughes • 20 July 2020 • 20:00
Preliminary testing of a coronavirus vaccine being developed by Oxford University in conjunction with an Italian company has triggered a strong immune response in its Phase 1 and 2 trials.
The Lancet report said the vaccine, worked on by Oxford’s Jenner Institute and Italian firm IRBM at Pomezia, “has induced a strong immune and anti-body response up to the 56th day of the ongoing testing”.
The vaccine was tested on 1,077 healthy adults in the first tests. Although the results of the preliminary stages are promising, the article comments, “Further studies are necessary to confirm is the vaccine effectively protects from COVID-19”.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you don’t already have one. Review our
Share your story with us by emailing [email protected], by calling +34 951 38 61 61 or by messaging our Facebook page www.facebook.com/EuroWeeklyNews
Your email address will not be published. Required fields are marked *
Download our media pack in either English or Spanish.